NEW YORK, June 1, 2026, 10:04 (EDT)
Maravai LifeSciences Holdings shares slipped 0.6% to $4.77 in early Monday trading. The stock is still up nearly 9% for the last five sessions and up about 47% this year. The Nasdaq-listed life sciences name has turned into a recovery play after seeing a steep post-COVID pullback.
That’s important now as the rebound’s early gains could be over. Investors want to see if demand for Maravai’s main businesses stays solid after one good quarter and a recent share rally.
Maravai LifeSciences Holdings, Inc. is set for its next public event on June 4. CFO Raj Asarpota will be speaking at the Jefferies Global Healthcare Conference in New York. The company said investors can access the webcast on its investor relations site.
Maravai’s latest 8-K wasn’t an operating update. In Friday’s filing, the company said shareholders picked Bernd Brust, Gregory T. Lucier and Luke Marker for new three-year board terms, signed off on Deloitte & Touche as auditor for 2026, and backed executive pay in a non-binding vote.
Maravai shares are still holding up on support from first-quarter earnings out in May. Revenue climbed 40.5% to $65.8 million. Net loss narrowed to $6.4 million. Adjusted EBITDA came in at $20.3 million. Free cash flow was $4.2 million.
Maravai CEO Bernd Brust said the company got off to “a strong start” and has “improving visibility” for the year. Maravai now sees 2026 revenue between $205 million and $215 million, up from its old range of $200 million to $210 million. It also boosted adjusted EBITDA guidance to $30 million to $32 million. Maravai LifeSciences Holdings, Inc.
Wall Street’s view is still split. StockAnalysis shows Deutsche Bank’s Justin Bowers and Stifel’s Daniel Arias put Buy ratings on the stock in May, both with $6 targets. William Blair’s Matt Larew is at Hold with a $3.94 target.
Life-sciences tools traded weaker early. Repligen slipped 2.5%, Thermo Fisher Scientific dropped 1.2% and Danaher lost 1.7%. The SPDR S&P Biotech ETF, an exchange-traded fund that holds a range of biotech stocks, was down 1.8%.
Maravai sells reagents and services for customers in biotech, biopharma, diagnostics, and vaccine development, as well as cell and gene therapy. The company’s main units are TriLink, which focuses on nucleic acid products, and Cygnus, which does biologics safety testing.
Maravai says the recovery could still be lumpy. In its latest quarterly filing, the company pointed to uncertainty around customer spending for both TriLink and Cygnus. Maravai said its operating results could swing, and sales of CleanCap for commercial vaccines are still unclear. The company also raised the risk of bigger competitors in life sciences, pharma and biotech.
Monday’s action seemed like a pause, not a shift, in this year’s trade so far. The bigger issue is if Maravai can follow up one good quarter and higher guidance with a better run through the rest of the year.
